双参口服液对醋酸泼尼松致骨质疏松症大鼠骨质和骨量的影响

背景：双参口服液由人参、丹参组成的复方，初次用于糖皮质激素类药物致导骨质疏松方面的研究。 目的：通过糖皮质激素建立大鼠骨质疏松动物模型，观察双参口服液对大鼠骨质和骨量的干预作用。 设计、时间及地点：随机对照动物实验，于2008-06/09在广东医学院动物实验中心及药理教研室完成。 材料：双参口服液高剂量制剂是用丹参3.6 kg，人参5 kg，加水水提2次，质量浓度为870 g/L；在此基础上稀释3倍，得到低剂量制剂，质量浓度为290 g/L。醋酸泼尼松原料药为浙江仙琚制药股份有限公司产品。 方法：SPF级3月龄雄性SD大鼠32只，随机分为4组，每组8只。正常对照组上午给予蒸馏水5 mL/(kg•d)灌胃，醋酸泼尼松组给予0.7 g/L醋酸泼尼松混悬液5 mL/(kg•d)灌胃。双参组先给予0.7 g/L醋酸泼尼松混悬液5 mL/(kg•d)灌胃后3 h，分别给双参口服液高、低剂量制剂按5 mL/(kg•d)灌胃。88 d后心脏抽血处死大鼠。 主要观察指标：检测各组大鼠体质量，单位骨中骨矿及骨羟脯氨酸含量；检测各组大鼠左股骨骨密度；右股骨生物力学指标。 结果：长期应用醋酸泼尼松抑制大鼠体质量增长(P < 0.01)，骨钙、骨羟脯氨酸含量和骨密度明显减少(P < 0.01或0.05)，股骨的最大载荷、弹性载荷和弯曲能量均减小(P < 0.01或0.05)。双参口服液无论高剂量还是低剂量用药对上述指标均有不同程度的改善(P < 0.01或0.05)。 结论：长期应用醋酸泼尼松可致骨质丢失，骨密度降低，骨生物力学特性降低。双参口服液在所用剂量下具有预防醋酸泼尼松致大鼠骨质疏松的作用。

Effects of Shuangshen oral liquid on glucocorticoid-induced osteoporosis rats

BACKGROUND: Shuangshen oral liquid consisting of renshen and danshen is firstly used to treat glucocorticoid-induced osteoporosis. OBJECTIVE: To establish a rat osteoporosis model through glucocorticoid and to observe the preventive effects of shuangshen oral liquid (SS) on bone substance and bone mass. DESIGN, TIME AND SETTING: A completely randomized controlled grouping animal experiment was performed in the Animal Experimental Center and Department of Pharmacology, Guangdong Medical College from June to September in 2008. MATERIALS: High-dose SS consisted of 3.6 kg danshen, 5 kg renshen, and then prepared by water extraction twice, and the concentration was 870g/L. On this basis, high-dose SS was diluted three times to obtain low-dose SS with a concentration of 290 g/L. The prednisone acetate raw medicine was purchased from Zhejiang Xian Ju Pharmaceutical Co., Ltd. METHODS: Thirty-two 3-month-old male SPF rats were randomly divided into 4 groups, and every group had 8 rats. The normal control group rats were fed with distilled water 5 mL/(kg.d) by gavage. Rats in prednisone group were treated with 0.7 g/L prednisone suspension (5 mL/kg per day) by gavage. SS group rats were treated with 0.7 g/L prednisone suspension (5 mL/kg per day) by gavage and then given the high does and low does SS (5mL/kg per day) respectively by gavage 3 hours later. The rats were sacrificed by heart hemospasia 88 days later. MAIN OUTCOME MEASURES: Body mass, bone mineral content and bone hydroxyproline content per unit bone, bone mineral density in the left femur, biomechanics indexes of the right femur. RESULTS: The long-term administration of prednisone restrained the increasing of rats body mass (P < 0.01); bone calcium content, bone hydroxyproline content and bone mineral density decreased significantly (P < 0.01 or P < 0.05); the maximum load, elastic load and bending energy of the femur had a obvious decrease (P < 0.01 or P < 0.05). Either high-dose or low-dose SS had a certain prevention and cure action (P < 0.01 or P < 0.05). CONCLUSION: Long-term administration of prednisone can induce bone loss, decrease bone mineral density and bone biomechanics properties. However, SS can significantly inhibit prednisone-induced osteoporosis in rats.